Abstract: Opioids are highly addictive substances with a relapse rate of over 90%. While preclinical 22 models of chronic opioid exposure exist for studying opioid dependence, none recapitulate the relapses 23 observed in human opioid addiction. The mechanisms associated with opioid dependence, the 24 accompanying withdrawal symptoms and the relapses that are often observed months or years after opioid 25 dependence are poorly understood. Therefore, we developed a novel model of chronic opioid exposure 26 whereby the level of administration is self-directed with periods of behavior acquisition, maintenance and 27 then extinction alternating with reinstatement. This profile arguably mirrors that seen in humans, with 28 initial opioid use followed by alternating periods of abstinence and relapse. Recent evidence suggests that 29 dietary interventions that reduce inflammation, including omega-3 fatty acids such as docosahexaenoic 30 acid (DHA), may reduce substance misuse liability. Using the self-directed intake model, we characterize 31 the observed profile of opioid use and demonstrate that a diet enriched in polyunsaturated fat acids 32 (PUFAs) ameliorates oxycodone-seeking behaviors in the absence of drug availability and reduces anxiety. 33
Introduction 45
Several factors converged in the early 2000s to contribute to the escalating opioid epidemic. These 46 included an over-prescription of potent and synthetic opioids, a belief that chronic pain was protective 47 against the development of addictive behavior, an aggressive marketing strategy by the manufacturers, 48 and the incorrect translation that long-term use of extended release opioids, safe in terminally-ill cancer 49 patients, could be used in non-cancer patients without caution [1] . Alarming statistics from recent years 50 document the increase in mortality from the use of fentanyl other synthetic opioids that are often prescribed 51 for pain [2] [3] [4] [5] . For many of these cases, the initial exposure to opioids began with oxycodone and other 52 prescription analgesics and was then transferred to other more rapidly acting opioids [6] . We demonstrate 53 in this paper that rapidly acting opioids are powerfully reinforcing and that dietary supplementation of 54 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acids (DHA) may reduce the ability of these 55 rapid-acting and potent compounds to maintain addictive-like behaviors via action on gut microbiome 56 composition. 57 58
Whichever the opioid, an inherent property of these addictive substances is the high rate (~91%) of 59 relapse [7] and the relative lack of effective treatment [8] . The rate of relapse following chronic opioid use 60 has been linked to allostatic mechanisms that maintain persistent drug seeking such as a decline in 61 cognitive control over habituated behaviors and tolerance to drug effects over time. The mechanisms that 62 produce these long-lasting addictions are complex and can induce cravings that lead to relapse months or 63 years after the physical opioid dependence is no longer a factor. According to the iRISA model of addiction 64
proposed by Rita Goldstein and colleagues, the increased salience of drug-paired cues and impaired 65 response inhibition in the absence of drug contribute to increased drug seeking over time and a persistence 66 of seeking in the absence of drug [9] [10] [11] . These physical and emotional changes result in a persistent 67 negative emotional state culminating in an inability to transition to an opioid-free state and to remain 68 opioid-free [12] . Coupled with an increased vulnerability to stress and both physical and psychological 69 stressors that trigger drug use in drug addicted humans and animals [13] , relapse after prior opioid use is 70 a common occurrence that must be addressed. 71 72
Several studies have focused on the bidirectional communication that takes place between the 73 gastrointestinal tract and the central nervous system (CNS). Previous studies have revealed the major role 74 gut microbiota have on brain function and consequently, neuropathology [14] [15] [16] [17] [18] . Anxiogenic affective-like 75 behaviors are lower in mice that exhibit increases in specific genera including Lactobacillus and 76
Bifidobacterium and these changes were linked to altered neural function [19, 20] . A similar relationship 77
between Bifidobacterium and anxiety in humans has been established [21] . Still, the role of nutrition and 78 supplementation in the microbiome-brain axis in psychiatry is not fully understood. 79 80 DHA is an essential long chain PUFA (DHA c22:6n-3) that is obtained from dietary sources and 81 supplementation. The beneficial effects of supplementary DHA for many conditions and diseases have 82 been the subject of ongoing research. A recurrent observation is that dietary omega-3 supplementation 83 relieves anxiety and depression symptoms in mood disorders often co-diagnosed in substance abuse 84 disorder patients (reviews; [22] [23] [24] . Accordingly, n-3 supplements enriched in DHA have been shown to 85 reduce anxiogenic affective-like behaviors in preclinical models [22, 25, 26] and clinical trials [23, [27] [28] [29] [30] [31] . 86 DHA is required as a structural component of plasma, microsomal and synaptic membranes in the brain 87 [32, 33] and is essential for numerous brain functions including development [34] , and diverse cellular 88 functions [35] [36] [37] [38] [39] . There is also evidence that DHA supplementation has an effect on the gut microbiota, 89 which can contribute to changes in brain function [40] [41] [42] . The overarching hypothesis for our study is that 90 DHA intake induces a beneficial shift in gut microbiome composition to normalize the genera that become 91 overgrown with opioid-self administration. 92 93
We have previously shown that chronic, noncontingent, morphine induces diverse adaptations of the 94 glutamatergic system in the striatum, a hub of the reward-centered mesolimbic circuitry [43] . Many of these 95 cellular and behavioral adaptations were reduced or offset by a PUFA-enriched diet. The model of opioid 96 exposure used in this previous study was an escalating dose of morphine, administered over 5 days by 97 subcutaneous injection twice daily, followed an additional 3 days of morphine (at the highest dose) by a 98 noncontingent method of delivery. In the present study, we used an opioid exposure model with greater 99 predictive and face validity to mimic opioid use disorder. This model uses a contingent exposure whereby 100 there is a choice as to how much opioid to self-administer through an indwelling intravenous catheter. The 101 delivery of each drug infusion was contingent on pressing a designated active lever in an operant box. This 102 allowed us to generate a profile of opioid use beginning with the acquisition of this behavior, followed by 103 a period of maintenance, then periods of extinction alternating with reinstatement. This profile of opioid 104 self-administration arguably recapitulates that seen in humans -with initial opioid use followed by 105 alternating periods of abstinence and relapse. Using this model, we first outline this opioid use profile and 106
then asked to what extent a PUFA enriched diet may alter drug-seeking behaviors. We also assessed to 107 what extent the DHA supplementation had on affective-like behavior using a light dark test. We then 108 examined how the chronic opioid self-administration and the DHA supplementation, separately and in 109 combination, altered gut microbiome composition. We achieved this by examining the gut microbiome 110 during multiple phases of the opioid exposure model. Lastly, we examined the state of the microglia in the 111 striatum, a site we had previously studied [43] , at the completion of the trial to determine if there was 112 evidence of altered microglial activation due to the opioid exposure or DHA supplementation. 113
Materials and Methods 114
All the experiments were conducted in accordance with the AALAC Guide for the Care and Use of 115 Laboratory Animals and approved by the UCLA IACUC committee (OARO #1999-179). Mice (C57Bl6/J Jax 116 stock # 000664), 6-8 weeks of age at the start of the experiment, were randomly assigned to a control lab 117 chow diet containing 0.5% DHA (Control) alone or supplemented with 2.5% DHA, 1.1% EPA and 0.75% 118 other omega-3 PUFAs, (Nordic Naturals, Watsonville, CA) for 8 weeks. As we have previously shown a 119 relative lack of effect of this DHA supplementation protocol on DHA enrichment in specific brain regions 120 in female C57Bl6/J mice [43] , only male C57Bl6/J mice were used for these experiments. Where possible, 121 experimenters were blind to treatment and diet for both behavioral testing and data analyses. 122 123
Intravenous self-administration (IVSA) administration. Mice were divided into 4 groups: control diet + saline 124 (n=14), control diet + opioid (n=14), DHA diet + saline (n=5), and DHA diet + opioid (n=10). An intravenous 125 catheter (0.2 mm i.d., 0.4 mm o.d., Cathcams, Oxford, UK) was inserted into the right jugular vein of mice 126 under sterile conditions as others and we have previously described [44] [45] [46] . Post-operative care included 127
Carprofen gel food (MediGel CPF, Portland, ME, USA). Catheters were flushed daily with 0.02 ml 128
Heparin/saline (30 USP/ml). The overarching timeline of experiments is described in Figure 1 . Mice were 129 monitored twice daily for the first 48h after surgery and exclusion criteria of more than a 15% weight lost 130 or a moribund state for over 24h were applied. Catheter patency was tested using an infusion of propofol 131 (20 μl of 1% propofol w/v in saline) every five days. After 3 days of postoperative recovery, mice were 132 trained to lever press in the self-administration operant boxes (Med-Associates Georgia, VT, USA) by using 133 a droplet of 20% sweetened condensed milk placed above both the active (AL) and inactive (IAL) levers 134 (3x per session) during the first two 120 min sessions. Mice underwent daily 2h self-administration sessions 135 where the active lever was paired with remifentanil and inactive lever was paired with saline infusion 136 using a random lever-infusion assignment (Figure 1 ). An AL press resulted in an intravenous drug infusion 137 (0.67μl/g body weight) and the presentation of a 10s tone and visual cue (light), together these comprise a 138
"reinforcer" (RNFS). A 10-s 'timeout' period followed each RNFS during which time no further RNFS could 139 be earned. The mice first underwent a minimum of 3 days of acquisition training using remifentanil (0.05 140 mg/kg/infusion) as the delivered opioid at a fixed ratio of one drug infusion for each lever press (FR1) to a 141 maximum of 50 RNFS or 2h, whichever came first (the acquisition phase). Once the criterion of 50 RNFS or 142 20% stability was obtained for 2 consecutive days, the mice were transitioned to oxycodone (0.25 143 mg/kg/infusion) under the same short-access 2h FR1 schedule for 10 days (the maintenance phase). This 144 was followed by 5 days of extinction (1E) in which no further drug was delivered in response to AL-145 pressing but the same environment and reward-associated cue conditions were presented but with no limit 146 on the number of RNFS that could be earned with the session ending after 2h. This was followed by a 2-147 day period of reinstatement in which oxycodone was administered intravenously at the same dose and 148 cues as used during maintenance. Thereafter the mice underwent a second extinction for an additional 5 149 days under the same conditions as during the first extinction with no limit on the number of RNFS that 150 could be earned and the session ending after 2h (2E). Due to the loss of catheter patency, the number of 151 mice in these later stages declined from those at the beginning of the experiment. Statistical Analyses. The 152 inter-and intra-session data were analyzed as a function of group and time using a linear mixed model in 153 R (R Core Team, 2015) using the package "lmerTest" [47] . The linear models were generated for each 154 experimental group of interest. The models were used to assess the effect of time, diet group, or an 155 interaction of these factors on AL presses and RNFS earned. Whenever a significant effect was observed, a 156 new reduced model was generated by removing the significant factor and compared with the original 157 model using an ANOVA in order to assess the impact of the respective factor on the goodness-of-fit for the 158 model. The resulting model is a regression equation where the intercept is allowed to vary for each subject: 159 YCharacteristic = β0 + βGroup XGroup * βTime XTime + USubject where YCharacteristic is the characteristic being modeled (e.g., 160
active lever presses, reinforcers earned), each predictor variable is represented by its subscripted X, and 161
USubject represents the random effect of each individual subject. The coefficients (β) are estimated and 162 assessed for significance and the contribution to the goodness of fit of the model was assessed. 163 164
Light dark assay. The apparatus consisted of light and dark compartments of a square box (28cm 2 square 165 18cm height) separated by a guillotine door in a quiet room illuminated at 50-55 lux. The light compartment 166 was illuminated at 1000 lux by a halogen lamp, measured at the guillotine door. Mice (control diet; n=7, 167 DHA diet; n=7) were placed in the dark compartment with the door closed for 2 minutes after which the 168 guillotine door was raised to allow free movement between the light and dark compartments for an 169 additional 2 minutes. Video tracking was recorded by a A1300-60gm Basler ace camera (106580-08, Basler, 170 Germany), saved by the downloadable VLC video software (VideoLAN) and analyzed for the time for a 171 full body exit from the dark compartment by experimenters blind to diet and opioid treatments. Statistical 172
Analysis. Data were analyzed by Linear Mixed Models as previously described [48] . This test was conducted 173 3 days before insertion of the intravenous catheter and just before the operant session on the second day of 174 the second extinction period (25 days after the initial test). 175 176
Microbiome characterization: 16S ribosomal RNA sequencing. Stool collection was done at the following time 177 points: baseline (control diet; n=5, DHA diet; n=3), 1 st day of oxycodone IVSA (control diet; n=11, DHA diet; 178 n=11), 10 th day oxycodone IVSA (control diet; n=15, DHA diet; n=10), 5 th day of first extinction (control diet; 179 n=15, DHA diet; n=10), and 1 st day of second extinction (control diet; n=7, DHA diet; n=7). Stool was 180 collected a minimum of 30 minutes before any behavioral tests, including IVSA. Stool was collected fresh, 181
and did not interact with any non-sterile surfaces. Mice were placed on top of cage (to provide them with 182 something to hold onto), held gently at the base of their tails and massaged until stool started to be naturally 183 expelled. Once stool was partly exposed, sterile forceps was used to remove the stool and place it into a 184 sterile tube. Within 2 minutes of extraction, they were placed in an -80C freezer and stored for 2-3 months 185 prior to 16S rRNA sequencing. DNA was extracted from frozen fecal pellets using the PowerSoil DNA 186
Isolation Kit (MO BIO Laboratories, Carlsbad, CA) with bead beating following the manufacturer's 187 instructions. The V4 region of 16S ribosomal RNA genes was amplified and underwent 2x150 sequencing 188 on an Illumina MiSeq as previously described [49] . The base pair reads were processed using QIIME v1. IBA1 and CD68 labeling. Brains from the four testing groups including the control diet + saline (n=2), control 208 diet + oxycodone (n=2), DHA diet + saline (n=2), and DHA diet + oxycodone (n=5) were collected 48h after 209 the last operant session. They were then placed in 4% paraformaldehyde overnight at 4C followed by 24-210 48h in 30% sucrose until equilibrated, then frozen in a dry ice/ isopropanol bath and stored at -80C. Fifty 211 μm sections were later cut and collected into phosphate buffered saline (PBS), washed in PBS with 0.1% 212 Triton X-100 (Sigma, MO, PBS-T) 3 x, 10' each, and blocked for 2h at RT in 5% NGS + 3% BSA in PBS-T. 213
They were then incubated in the following antibodies diluted in the wash buffer; anti-rabbit IBA-1 (1;2,000, 214
Wako, Richmond VA, cat. # 019-19741) and anti-mouse CD68 (1:1000, BioRad Hercule, CA, USA, cat. # 215 MCA 1957) overnight at 4°C. After another 3 washes for 10' each, sections were incubated in the following 216 secondary antibodies; goat anti-rabbit 488 (1:1000) and goat anti-Rat 647 (1:1000, both from Thermofisher, 217
Waltham, MA) diluted in PBS-T, for 2h at RT. After a final 2 washes in PBS-T and one in PBS for 10' at RT, 218 the sections were mounted on Permamount slides and coverslipped with a DAPI Antifade mounting 219 medium (VectorLabs, Burlingame, CA). A Leica DM5500 B upright microscope with a Leica DFC9000 GT 220 sCMOS camera and LAS X software (Lieica, Germany) and a 20x objective was used to obtain tiled images 221 of each section. Sections (10x10") from dorsomedial and dorsolateral regions of the striatum were exported 222 to ImageJ [54] . Statistical Analyses. The shape and intensity of CD68 labeled cells was quantified by a user 223 blind to the group identity with 5-30 cells quantified in each image and 5-10 images quantified for each of 224 the dorsolateral and dorsomedial striatal sections of each mouse, and as there was no effect of region, they 225 were combined into a single dataset for analysis by one-way ANOVA (Prizm v8). 226 227
Results 228

The experimental timeline. 229
A schematic of the timeline used is shown in Figure 1 and described as follows. The basal light dark 230 test and fecal collection occurred prior to the IVSA surgery which was then followed by the IVSA self-231 administration protocol consisting of 5 sequential phases; acquisition, maintenance, extinction, 232 reinstatement, and a second extinction. Fecal collection was performed between each of these phases with 233 the final light dark test taking place on day 24 during the second extinction. To both characterize the opioid self-administration profile and to assess the effect of a DHA-enriched 251 diet on this profile, mice maintained on a standard laboratory chow diet were compared to mice given an 252 increased level of DHA supplemented into the food. Both groups of mice were trained to self-administer 253 opioids in order to analyze drug specific behaviors, the first when remifentanil was self-administered 254 ( Figure S1A-S1B ) and the second when oxycodone was self-administered (Figure 2A-2F ). 255 256 257 
279
Mice underwent at least three days of acquisition training using remifentanil as the delivered opioid 280 on an FR1 schedule. There was no effect of diet in the initial acquisition of opioid self-administration; using 281 remifentanil as the reinforcer, neither active lever presses (F (2,88) =1.185, p=0.3) nor reinforcers (F (2,88) =0.837, 282 p=0.44) were significantly different between diet groups (Figure S1A-S1B) . 283 284
The number of AL presses across this profile showed an effect of day (p<0.001, χ 2 = 12.147) and diet 285 (p<0.05, χ 2 = 4.646), as well as, a significant day-by-diet interaction (p<0.01, χ 2 = 7.526). For mice on the 286 control diet, post-hoc analysis revealed an increase in AL pressing on 1E1 (p<0.0001, χ 2 = 21.367) and a 287 decline in lever pressing thereafter during sessions 2E2-5(p<0.0001, χ 2 = 31.481). AL pressing during 288 reinstatement did not differ from the last day of the first extinction period (1E), but again increased on the 289 first day of 2E following the 2-day reinstatement of oxycodone (R1 or R2 vs 2E1; p<0.01, χ 2 = 7.164). For 290 mice on the DHA diet, post-hoc analysis showed an initial similarity as those on the control diet with an 291 increase in lever pressing on 1E1 (p<0.01, χ 2 = 10.583) and a decline in lever pressing for each day of 1E 292 thereafter (p<0.0001, χ 2 = 20.022). However, the second extinction period following the 2 reinstatement 293 sessions did not induce an increase in ALs. Furthermore, AL pressing across sessions 2E1-5 by the DHA 294 mice was lower than that of the control mice (p<0.05, χ 2 = 5.136) (Figure 2A) . These results are consistent 295 with the DHA-enriched diet reducing oxycodone seeking behaviors during the second but not first 296 extinction period. 297 298
In assessing goal-directed lever pressing behavior, the number of inactive (no drug infusion) lever 299 presses showed significant day-by-diet interaction (p<0.05, χ 2 = 4.775); however, there was no independent 300 effect of diet, (p=0.70, χ 2 = 0.143) or day (p=0.58, χ 2 = 0.305) on this parameter ( Figure 2B ). Goal-directed 301 lever pressing behavior can also be evaluated by the percent of active lever presses out of the total lever 302 presses (AL/(AL + IAL)). This showed an effect of day (p<0.0001, χ 2 = 19.231), but not diet (p=0.67, χ 2 = 0.178) 303 nor any day-by-diet interaction (p=0.69, χ 2 = 0.156) ( Figure 2C ). 304 305
A press on the AL followed by the delivery of oxycodone or saline, a tone and 10s visual light cue, and 306 a 10s time-out period together comprised the reinforcer (RNFS). When measuring the number of RNFS 307 earned, we found that this parameter mirrored the AL presses in that there was a day (p<0.01, χ 2 = 10.361) 308 and diet effect (p<0.05, χ 2 = 4.694), as well as a day-by-diet interaction (p<0.01, χ 2 = 9.726). Further post-hoc 309 analysis showed that, for mice on the control diet, the number of RNFS earned increased on 1E1 (p<0.0001, 310 χ 2 = 16.547) and declined thereafter (p<0.0001, χ 2 = 25.288). The number of RNFS obtained during 311 reinstatement did not differ from the last day of E1 and were lower than the last day of maintenance (p<0.01, 312 χ 2 = 10.538). However, there was an increase in RNFS earned on the first day of the second extinction period 313 (2E1) above that of reinstatement (R1 vs 2E1; p<0.01, χ 2 = 7.790). For mice on the DHA diet, post-hoc analysis 314 revealed an initial similarity with those on the control diet showing an increase in RNFS earned on 1E1 315 (p<0.0001, χ 2 = 17.498) and a decline in RNFS for each day of 1E thereafter (p<0.0001, χ 2 = 20.478). However, 316 the 2E1-5 sessions did not induce an increase in RNFS earned when compared to the level observed during 317 reinstatement. Furthermore, RNFS earned by the DHA mice across the five days of this 2E period were 318 lower than that of the control mice (p<0.01, χ 2 = 6.842) ( Figure 2D ). 319 320 Given our observation that the first day of 2E showed a clear protective effect for the DHA diet on 321 opioid seeking behaviors, we then focused on the within-session behavior. Specifically, we analyzed the 322 rate of AL pressing or RNFS earned within the 2 h access window on the first day of 2E. Using mixed 323 models linear analysis of these datasets we found that the rate of AL pressing showed an effect of diet 324 (p<0.05, χ 2 = 3.889), time (p<0.0001, χ 2 = 30.788), and an interaction of diet and time (p<0.01, χ 2 = 6.800) with 325 the control group pressing more frequently than the DHA group (Figure 2E-2F) .Further in-depth analysis 326 of the hourly data showed an effect of diet (p<0.05, χ 2 = 4.018), but not time, on the frequency of AL pressing 327 with the control group pressing more during the first hour. During the second hour, the frequency of AL 328 pressing declined resulting in an effect of time (p<0.05, χ 2 = 4.155), and a diet-by-time interaction (p<0.05, 329 χ 2 = 4.884), but no effect of diet alone ( Figure 2E) . In contrast, the rate of RNFS earned did not show any 330 clear effect of diet, time, nor an interaction between the control and DHA diet for the entire 2h session. 331
Post-hoc analysis of each hour revealed no significant difference in RNFS earned during the first hour. 332
However, there was an effect of diet (p<0.01, χ 2 = 7.254), time (p<0.01, χ 2 = 8.041), and a diet-by-time 333 interaction (p<0.001, χ 2 = 10.993) for the second hour. This was due to the rate of RNFS earned by the DHA 334 mice declining more rapidly than the control group during this hour ( Figure 2F) . We characterized the effect of DHA on gut microbiome composition in the context of opioid exposure 344 by performing 16S rRNA sequencing of fecal samples collected from the two dietary groups at baseline, 345 during oxycodone maintenance (days 1 and 10), 1E, and 2E. There was a significant difference in overall 346 microbial composition between mice on the control diet and mice on the DHA-enriched diet (p-value <0.05) 347 after adjusting for study phase ( Figure 3A) . There was also a significant difference in the microbiome 348 during the oxycodone maintenance phase as compared to both extinction group periods (1E & 2E) while 349 controlling for diet (p-value <0.05). There was no statistical difference between microbiome profiles at day 350 1 (D1-OXY) of oxycodone maintenance and day 10 (D10-OXY). There was also no statistical difference in 351 overall microbial composition between 1E and 2E. DHA supplementation lead to a significant increase in 
368
Differential abundance testing was performed at the genus level to identify microbes that were 369 associated with DHA supplementation during the oxycodone maintenance and opioid extinction phases 370 using DESeq2 models at a 5% false discovery rate threshold (q-value<0.05). DHA supplementation lead to 371 a significant decrease during the oxycodone maintenance phase in Akkermansia (4-fold) and Parabacteroides 372 (5.5-fold) and a significant increase in multiple genera including Lactobacillus (8-fold), Allobaculum (7-fold) 373
and Bifidobacterium (7-fold) ( Figure 4A ). During the opioid extinction phase, DHA supplementation was 374 similarly associated with depletion of Parabacteroides (3.4-fold) and enrichment of Bifidobacterium (8.5-fold), 375 but Lactobacillus was not significantly different and additional differences were observed including 376 increased Desulfovibrio (6-fold) ( Figure 4B) . Similar analysis was then performed to identify genera 377 associated with the opioid extinction phase compared to the oxycodone maintenance phase in one or both 378 diets. Opioid extinction led to a significant decrease in Akkermansia (64-fold) and Bifidobacterium (8-fold) 379 independent of diet. Opioid extinction also led to a significant decrease in Parabacteroides (5-fold) but only 380 within the control diet group (Figure 4C-4D) . Lactobacillus did not significantly change with opioid 381 extinction. 382 383 To assess the activation state of microglia we labeled these cells with 2 antibodies, one against CD68, 394 a lysosomal protein expressed in high levels in activated microglia [56] and one against IBA1, a calcium 395 binding protein found in microglia and macrophages [57] . This enabled us to count the number of CD68-396 labeled microglia in the dorsomedial and dorsolateral striatum and then assess the shape and density of 397 IBA1 labeling in these CD68-positive cells. A representative slice image is included in Figure 5A . 398 399 with an effect of DHA (***, p<0.001) but no effect of opioid exposure.
414
The DHA group showed a basal reduction in the number of CD68+ cells as compared to the control 415 diet group (F (3, 16) = 14.66, p<0.001; one-way ANOVA), but the opioid self-administration did not induce 416 any further change ( Figure 5B) . We next analyzed cell morphology by assessing cell area for the CD68+ 417 cells. The cell area of the control diet group, whether saline or opioid-treated, was lower than that of the 418 DHA control (p<0.001) or opioid self-administration (p<0.05) groups. There was no effect of opioid self-419 administration in the control diet group, but opioid exposure lead to a decrease the cell area in the DHA 420 group (F (3, 18) = 6.760, p=0.003, one-way ANOVA, Figure 5C ). Next, we measured the mean grey value or 421 average pixel density of the CD68+ cells. This analysis revealed that the DHA group had a significant 422 decrease in mean density compared to the control diet group, regardless of opioid exposure (F (3, 18) = 83.17, 423 p<0.001 in each diet group) ( Figure 5D ). However, there was no effect of opioid self-administration in either 424 diet group (p=0.4 in each diet group) ( Figure 5D ). We then measured the integrated density of CD68 425 immunolabeling by taking the sum of the pixels in the standardized selected area within the dorsal 426 striatum. This parameter was similarly altered by diet (F (3, 18) = 38.42, p<0.001) with the DHA group showing 427 a significant decrease in integrated density, but there was no effect of opioid exposure (p=0.95 in control 428 and p<0.9 in DHA groups) ( Figure 5E ). 429
Discussion 430
We have previously shown that a PUFA-enriched diet alters the behavioral and cellular adaptations 431 to non-contingent chronic morphine exposure [43] . The underlying mechanism causing the increase in drug seeking behaviors during the extinction cycle 476
is not completely understood and therefore it is also unclear how the DHA enriched diet led to a decrease 477 in these behaviors. Intuitively, it is assumed that the opioid conditioned response is to the positive 478 reinforcement associated with drug use, however, negative reinforcement mechanisms can drive the 479 compulsivity of drug addiction and relapse. The negative emotional state that is experienced during drug 480 abstinence following chronic opioid use and reinforcers paired with drug withdrawal have been shown to 481 lead to drug seeking behaviors [64] . Studies in mice and humans suggest that an elevated level of stress 482 and anxiety increase the probability of relapse and that exposure to stressors reliably reinstates drug 483 seeking behaviors even after prolonged drug-free periods. This negative emotional state and the associated 484 negative reinforcements may be the driving influence in our study that leads the control mice to increase 485 their drug seeking behaviors during the extinction phases of this behavior paradigm. The reduction in drug 486 seeking behaviors due to the DHA supplementation corresponded to gut microbiome changes during 487 opioid maintenance and withdrawal. The DHA supplementation could be playing a protective role in the 488 gut-microbiome by mitigating the microbiome changes (i.e., the reduction in Bifidobacterium) observed due 489 to opioid withdrawal during the extinction phase. The DHA enriched diet also alleviated the anxiety-490 associated behaviors in the light/dark test, which was induced by the opioid use and subsequent 491 withdrawal during the extinction period. There is a strong possibility that the effect of DHA 492 supplementation seen in the gut microbiome offset the increased levels of anxiety during forced 493 withdrawal period caused by extinction. 494 495
Intermittent noncontingent but not continuous morphine has been shown to alter the gut microbiome 496 and to induce neuro-inflammation. This can be offset by restoring the microbiome to control levels [65] . In 497 light of our findings that the DHA diet altered the gut microbiome and offset some of the opioid-induced 498 changes seen during the second extinction phase, we hypothesized that the PUFA-enriched diet would 499 reduce microglial activation induced by oxycodone self-administration. Assessing the size of the microglia, 500
identified by the presence of CD68 labeling and shape and intensity of IBA-1 label CD68 cells, we found 501 that this diet reduced the basal activation state of microglia, shown as an increase in size and reduction in 502 the number of cells and intensity of label. However, contrary to our hypothesis, there was no effect of 503 oxycodone self-administration on microglial activation. This may be a result of the low, continuous levels 504 and relatively short access (2 h) of opioid self-administered across the 27 days of the experiment, a regimen 505 that is similar to continuous opioid exposure [65] that may not induce measurable neuro-inflammation. 506
The low sample number of this experiment also warrants caution in furthering our interpretation of this 507 dataset. 508 509
This study outlines a profile of opioid self-administration of an initial maintenance phase followed by 510 periods of abstinence, when drug-seeking becomes pronounced, and may imitate relapse. It is this 511 heightened period of drug-seeking that can be reduced by supplemental DHA which, we also show, 512 reduces anxiety. We propose that such periods of opioid exposure and subsequent withdrawal generate a 513 long-term pathological state of anxiety that leads to the high rate of relapse associated with opioid use and 514 that this may be offset by DHA supplementation. As DHA has beneficial effects on the gut microbiome, 515 this PUFA may offset the effect of opioids on the gut-brain axis. The evidence for this interaction between 516 the gut microbiome and neuropathology continues to grow; we propose that this may be the link by which 517 
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